Assessment of Steroneo Skin Cream (Physalis Angulata Supercritical Extract) application for treatment of eczematous lesions
- Conditions
- Health Condition 1: null- Eczema of skin
- Registration Number
- CTRI/2016/11/007511
- Lead Sponsor
- Rehmat Clinic
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 50
Clinically diagnosed with eczematous lesions of any of the following types and requiring mild to moderate topical steroid therapy:
•Atopic dermatitis
•Contact dermatitis
•Xerotic eczema
•Nodular eczema
•Seborrheic dermatitis
•Neurocutaneous dermatitis (lichen simplex chronicus)
•Drug eruptions, photo-dermatitis
•Pruritus requiring topical corticosteroids
Patients/parents who sign the written informed consent form
Patients willing to and able to understand and comply with all study requirements
1.Patients having any of the following conditions:
•Lichen planus
•Severe dermatitis requiring systemic corticosteroids
•Infantile dermatitis
2.Patients requiring systemic corticosteroids on any form
3.Pregnant and lactating women
4.Patients with known hypersensitivity to any of the ingredients/excipients of the study cream
5.Any other condition, which in the opinion of the clinician/investigator, could interfere significantly with the treatment and assessment process
6.Use of any investigational therapy within 30 days prior to randomization
7.Patients not willing to provide written informed consent
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method